Allerton, Charlotte
Pfizer (United States)
3 papers on CoChatORCID 0000-0001-8665-159X
Most cited papers
- Verified
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., et al. (2021) · Science
SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies
Cited by 2,033
- Verified
Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)
Varma, M. V., Steyn, S. J., Allerton, C., & El-Kattan, A. F. (2015) · Pharmaceutical Research
Computational Drug Discovery MethodsDrug Transport and Resistance Mechanisms
Cited by 334
- Verified
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19
Boras, B., Jones, R. M., Anson, B. J., Arenson, D., Aschenbrenner, L., Bakowski, M. A., Beutler, N., Binder, J., Chen, E., Eng, H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory)
SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies
Cited by 154
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free